Get the latest Science News and Discoveries

New study demonstrates the efficacy of a promising celiac disease drug at the molecular level - EurekAlert


A recent study led by researchers at Tampere University investigated whether a transglutaminase 2 inhibitor has potential as a drug to treat celiac disease. Previous tissue studies have shown that the ZED1227 transglutaminase 2 inhibitor prevents gluten-induced intestinal damage. The results of the new study, based on an analysis of the molecular activity of more than 10,000 genes, provide very strong evidence that the first successful drug to treat celiac disease may be at hand.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of EurekAlert

EurekAlert

Photo of molecular level

molecular level

Photo of New Study

New Study

Related news:

News photo

Nanowires create elite warriors to enhance T cell therapy - EurekAlert

News photo

Ice recon: Satellite navigation breakthrough in mapping sea ice thickness - EurekAlert

News photo

DGIST-POSTECH joint research team developed next-generation impact-resistant stretchable electronic component - EurekAlert